Richard Stanley Bedlack
Professor of Neurology
Campus mail:
932 Morreene Rd Room234, Durham, NC 27705
Phone:
(919) 668-2839
Email address:
bedla001@mc.duke.edu
1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Education and Training
- EMG Fellow, Medicine, Duke University, 1999 - 2000
- Neurology Resident, Medicine, Duke University, 1996 - 1999
- Medical Intern, Medicine, Duke University, 1995 - 1996
- Ph.D., University of Connecticut, 1995
- M.D., University of Connecticut, 1995
Selected Grants and Awards
- Healey ALS Platform Trial Open Label Extension Zilucoplan
- A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
- Potential Role of the Gut Microbiome in ALS Progression and Reversals
- Potential Role of the Gut Microbiome in ALS Progression
- ALS Telemedicine
- The Duke ALS Association Certified Center
- I AM ALS
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE)
- EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN
PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING
STUDY 3119002 - ALS Telemedicine
- Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS)
- A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS)
- Duke ALS Telemedicine Clinic
- Integrated Genomics in Clinical ALS (GTAC)
- Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE)
- A Phase 2 Pharmacodynamic Study of Ezogabine on Neuronal Excitability in Amyotrophic Lateral Sclerosis
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
- A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)
- A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerabiliity and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis ( ALS)
- HDE Post-Approval Study (PAS) of NeuRx DPS for ALS